Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California. As of December 2, 2024, Longboard Pharmaceuticals, Inc. operates as a subsidiary of Langkawi Corporation.
Bexicaserin's Promise | Explore Longboard Pharmaceuticals' lead compound bexicaserin, a potential game-changer in treating developmental and epileptic encephalopathies with billion-dollar market potential. |
Pipeline Progress | Delve into Longboard's advancing clinical trials, including the upcoming Phase 3 epilepsy program for bexicaserin and early-stage developments of LP659 for neuroinflammatory conditions. |
Market Disruption | Learn how bexicaserin's favorable safety profile could reshape the competitive landscape, potentially outperforming existing treatments like Fintepla in efficacy and long-term safety. |
Analyst Optimism | Discover why analysts are bullish on Longboard, with price targets ranging from $60 to $90, reflecting confidence in the company's innovative approach to neurological treatments. |